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Analysis of Plasmodium falciparum isolates collected
before, during, and after a 1999 malaria epidemic in Djibouti
shows that, despite a high prevalence of resistance to
chloroquine, the epidemic cannot be attributed to a sudden
increase in drug resistance of local parasite populations.
F
rom March to June 1999, an epidemic of Plasmodium
falciparum malaria affecting all age groups spread in
the city of Djibouti, Horn of Africa, an area with low and
irregular transmission. Since the 1970s, autochthonous
cases of malaria have been reported among the local pop-
ulation, but their incidence is usually low (1). Anopheles
arabiensis, the main malaria vector in the city (2,3), has
been found since the 1970s, possibly from Ethiopia (1,4).
The focused distribution and the specificity of the breeding
sites allowed a control strategy based on treatment of the
larval sites with a larvivorous autochthonous fish, comple-
mented with pinpoint use of bacterial toxins (3).
Unfortunately, malaria control activities were progressive-
ly decreased so that, since the mid-1990s, vector control
activity has been reduced to irregular insecticide indoor or
outdoor spraying. Djiboutians frequently travel, and the
Djibouti-Ethiopian railway has been suspected to be an
effective route for propagating malaria parasites (5).
Although some chloroquine treatment failures were report-
ed in Djibouti in 1990 (6), most persons with P. falciparum
were treated by chloroquine or quinine at the beginning of
the 2000s, including during the 1999 epidemics. To deter-
mine whether this epidemic was associated with temporary
changes in environmental conditions or to importation of
new (virulent) or resistant P. falciparum strains, we inves-
tigated P. falciparum population diversity before, during,
and after the outbreak and analyzed in vitro susceptibility
profiles to a panel of antimalarials during the epidemics.
The Study 
The study was conducted at the Centre Hospitalier des
Armées Bouffard, a French military hospital in Djibouti
serving military and civilian natives from the entire city,
and at other public health facilities of Djibouti. From 1997
to 2002, clinical malaria in the hospital shows the same
temporal fluctuations as in dispensaries in the city
(Figure). The incidence of patients with P. falciparum
malaria admitted to the hospital increased >10-fold from
March to May 1999 compared with the same period in
1997, 1998, and 2000–2002. In contrast, the number of
admissions, consultations at the outpatient clinic, or blood
counts performed for other causes than fever did not vary
over the same period. The meteorologic station of the
international airport of Djibouti recorded heavy rainfall the
month before the epidemic. However, similar rainfall in
1997 or autumn 1999 was not followed by such a dramat-
ic increase in malaria incidence in the ensuing months
(Figure). When annual averages were compared, no partic-
ular variations in minimal or maximal mean air tempera-
tures were found to occur during the months preceding the
epidemic.
Forty-six blood samples were collected from
September 14 to December 31, 1998 (period 1), 61 from
April 12 to April 30, 1999 (period 2), and 32 from March
15 to May 15, 2002 (period 3), from patients with P. falci-
parum clinical cases who had not travelled outside the city
of Djibouti during the preceding month and declared not
having taken any antimalarial drug before the blood sam-
pling. The study was cleared by the Djibouti Ministry of
Health. Informed oral consent was obtained from patients
before blood collection. Venous blood was collected
before treatment administration in Vacutainer EDTA tubes
(Becton Dickinson, Rutherford, NJ, USA). Thin blood
smears were stained with an RALkit (Réactifs RAL, Paris,
France). Parasitemia was expressed as the proportion of P.
falciparum–infected erythrocytes. Aliquots of freshly col-
lected blood were kept at –20°C until DNA extraction. 
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Figure. Rainfall (bars) and monthly incidence of Plasmodium falci-
parum clinical malaria cases (curve) at the French Military Hospital
– CHA Bouffard (circle) and in the dispensaries of the city
(Department of Epidemiology and Public Hygiene. Triangle),
Djibouti city, January 1997–May 2002.P. falciparum genetic diversity was investigated by
using msp1 and msp2 encoding highly polymorphic loci
from merozoite surface protein genes. Msp1 and  msp2
were genotyped by using nested polymerase chain reaction
(PCR), as described (7), except that family-specific fluo-
rescent primers were used in the nested PCR for assign-
ment to the K1-, Mad20-, or Ro33-type msp1 family and to
the 3D7- or FC27-type msp2 family. Fragment length was
analyzed by the Genescan technology. Approximately 50%
of the blood samples contained multiple msp1 or msp2
genotypes. The mean multiplicity of infection, i.e., the
number of genotypes present in the blood sample, was
≈1.5 concurrent P. falciparum infections per person, with a
decreasing tendency over the study period (Table 1). For
each locus, multi-infection cases were excluded from
analysis of genetic diversity. We identified 9 msp1 alleles
in 83 isolates and 17 msp2 alleles in 108 isolates. The
genetic diversity estimated by the unbiased expected
DISPATCHES
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chosen genotypes are different in the sample, before, dur-
ing, and after the 1999 outbreak was 0.79 (n = 23), 0.37 (n
= 39), and 0.64 (n = 21) at the msp1 locus and 0.83 (n =
31), 0.34 (n = 47) and 0.63 (n = 30) at the msp2 locus,
respectively. During the epidemic, Ro33-131 accounted
for 79% of the msp1 allele and FC27-408 accounted for
81% of the msp2 alleles. Both alleles were present before
and after the epidemic but with a much lower prevalence.
They accounted for 26% of the msp1 and 35% of the msp2
alleles in 1998 and 14% of the msp1 and 10% of the msp2
alleles in 2002 (Table 2). 
To look for resistance-associated point mutations and
haplotypes, the complete coding region of Pfdhfr (dihydro-
folate reductase) and Pfdhps (dihydropteroate synthase)
was amplified and sequenced (ABI 3100 Genetic Analyser,
Applied Biosystems, Courtaboeuf, France) as described
(9). We focused the analysis on point mutations of Pfdhfr
codons 16, 51, 59, 108, and 164 and Pfdhps codons 436,
437, 540, 581, and 613, which have been associated with
resistance to pyrimethamine and proguanil metabolite and
to sulfadoxine, respectively (10). The prevalences of the
Pfdhfr and Pfdhps mutations are shown in Table 1. No
mutant was detected for Pfdhfr codons 16 and 164 and
Pfdhps codon 581. A single isolate collected in period 2
harbored the Pfdhps A613S mutation. No isolate harbored
the quintuple mutant haplotype (Pfdhfr S108N, N51I, and
C59R and Pfdhps K540E and A437G) or the Pfdhfr C59R
and Pfdhps K540E combination that predicts sulfadoxine-
pyrimethamine clinical failure (9). One isolate containing
at least 2 P. falciparum populations harbored 3 Pfdhfr
mutations (S108N, N51I, and C59R) and the Pfdhps
K540E mutation.
From 1998 to 1999, the frequency of isolates with
mutated Pfdhfr codons 51, 59, and 108 decreased (not sig-
nificantly), and Pfdhps allelic frequency did not differ sig-
nificantly. The prevalence of isolates harboring the Pfdhfr
N51I, Pfdhfr S108N, Pfdhps A437G, and Pfdhps K540E
mutations increased from 1998–1999 to 2002 (Fisher exact
test, p < 0.001 each). Presence of the chloroquine resist-
ance–associated K76T mutation of Pfcrt (chloroquine-
resistance transporter) (11) was analyzed by nested
allele–specific PCR. Over the study period, 93% of the iso-
lates harbored the Pfcrt K76T mutation (Table 1), without
any significant temporal variation.
Twenty seven P. falciparum isolates collected during
the 1999 epidemic with a 0.05%–5.0% parasitemia were
transported at 4°C to our laboratory in Marseille, France,
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topic microtest (12). Among them, 93% were classified as
resistant to chloroquine (Table 3). No isolate was resistant
to amodiaquine. In vitro resistance was 4% for both
pyrimethamine and cycloguanil. 
Conclusions
Before and after the 1999 epidemic, P. falciparum
genetic diversity in Djibouti was large, with ≈80% and 63%
heterozygocity. This finding is somewhat surprising for an
area where disease endemicity is low (13) and probably
reflects importation of strains from neighboring areas such
as Ethiopia or Somalia (1,5). P. falciparum genetic diversi-
ty was diminished during the epidemic, reflecting the circu-
lation of a restricted number of strains during that period.
Most of these strains harbored an msp1 and msp2 genotype
that was detected before the epidemic. The prevalence of
Pfcrt, Pfdhfr, and Pfdhps mutant genotypes did not vary
significantly from 1998 to 1999. Thus, our data do not sup-
port the hypothesis of a sudden increase in the drug resist-
ance of the local P. falciparum population as causing the
epidemic. Our data are also not consistent with massive
invasion by a single strain/genotype but rather suggest
expansion during the epidemic of a few strains that were
already prevalent. Further genotyping is needed to establish
how many strains were circulating and their possible origin.
What could have caused this sudden amplification? One
possibility is a temporary increase in vector density.
Unfortunately, no vectors were captured at that time, and
this hypothesis is difficult to explore retrospectively. 
The low prevalence of Pfdhfr and  Pfdhps resistance
mutations in 1998 and 1999 and of proguanil or
pyrimethamine in vitro resistance in 1999 may explain the
very low incidence of clinical malaria among the French
soldiers stationed in Djibouti who were taking chloro-
quine-proguanil chemoprophylaxis. However, the sharp
increase of Pfdhfr and  Pfdhps resistance mutations
observed in 2002 threatens sulfadoxine-pyrimethamine
efficacy in the near future, even more so since the limited
acquired immunity is unlikely to contribute to sustained
drug efficacy (14). Molecular and in vitro assays point to a
very high prevalence of chloroquine resistance. This find-
ing calls for an urgent in vivo assessment of the antimalar-
ials presently used in Djibouti in order to consider a rapid
change in first-line treatment policy. 
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